How to Engineer Developable Antibodies: AI-Driven Optimization

You've identified that your antibody has developability liabilities—aggregation at high concentration, high viscosity, or chemical instability. Now what? Abandoning the program means losing millions in investment. Starting over means years of delay while competitors advance.

The solution: Engineer developability into your candidate using AI-driven prediction and rational protein design. Here's the complete workflow, from computational screening to IND filing, with real rescue stories and practical protocols.

Key Takeaways

• 2-5× improvement in success rates with early developability screening

• 6-12 months faster timelines compared to trial-and-error optimization

• $20-50M saved per program by avoiding late-stage failures

• AI prediction (Orbion) identifies issues in minutes vs months of experimental testing

• 1-3 mutations can rescue a failed antibody candidate

• Glycosylation at Asn297 is critical for Fc effector function (ADCC/CDC)

The Developability Assessment Workflow

Stage 1: Discovery (Antibody Generation)

Goal: Identify high-affinity binders

Methods:

• Phage display: Library screening (10⁹-10¹¹ variants)

• Hybridoma: B-cell fusion (mouse/rat immunization)

• Single B-cell cloning: From immunized animals or humans

• In silico design: Computational antibody design (emerging)

Output: 10-100 antibody candidates with Kd < 10 nM

Traditional problem: No developability filtering at this stage

Stage 2: Early Developability Screening (The Critical Step)

Goal: Filter out candidates with developability liabilities BEFORE investing in lead optimization

This is where the new paradigm differs from traditional approaches. Instead of advancing all high-affinity candidates, we computationally predict developability and filter early.

Computational Predictions (1-2 weeks, minimal cost)

A. Aggregation Propensity Prediction

Tools: Orbion, AGGRESCAN3D, CamSol, SAP

What it does:

• Analyzes protein structure (AlphaFold or homology model)

• Identifies surface-exposed hydrophobic patches

• Calculates aggregation propensity score per residue

• Highlights hotspot residues in CDRs and frameworks

Output:

• Aggregation risk score (low/medium/high)

• 3D visualization of hydrophobic patches

• Specific residues driving aggregation

Example:

• Antibody A: CDR-H3 sequence YYFDY (4 aromatic residues clustered)

• AGGRESCAN3D score: 620 (high risk, threshold >500)

• Decision: Deprioritize or redesign CDR-H3

B. Viscosity Prediction

Tools: Orbion, PIPP (Protein Interaction Property Prediction)

What it does:

• Maps charge distribution on antibody surface

• Identifies charge patches (positive and negative clusters)

• Predicts viscosity at 150 mg/mL using protein-protein interaction models

Output:

• Estimated viscosity (cP)

• Charge patch visualization

• Residues contributing to charge anisotropy

Example:

• Antibody B: Large positive patch (7 Lys/Arg) on VH, large negative patch (5 Glu/Asp) on VL

• Predicted viscosity: 75 cP (target <20 cP)

• Decision: Design charge-balancing mutations

C. Thermal Stability Prediction

Tools: Orbion (ΔΔG predictions), Rosetta, FoldX

What it does:

• Predicts melting temperature (Tm) for each domain

• Identifies destabilizing mutations or regions

• Suggests stabilizing mutations

Output:

• Tm estimates for VH, VL, CH2, CH3

• Stability score per domain

• Mutation recommendations

D. Chemical Stability Hotspots

Tools: Orbion (PTM prediction), sequence analysis

What it does:

• Scans for liability sites:

  • Asn-Gly (deamidation)

  • Asp-Gly (isomerization)

  • Met in CDRs (oxidation)

  • Unpaired Cys (disulfide scrambling)

Output:

• List of liability sites with predicted degradation rates

• Severity ranking (high/medium/low risk)

E. Immunogenicity Risk Assessment

Tools: Orbion (T-cell epitope prediction), IEDB, EpiMatrix

What it does:

• Identifies non-human germline residues

• Predicts MHC-II binding peptides (T-cell epitopes)

• Scores immunogenicity risk

Output:

• Humanness score (% identity to human germline)

• T-cell epitope map

• High-risk regions for humanization

Rapid Experimental Screening (3-4 weeks)

After computational filtering, test top 10-20 candidates experimentally:

F. Small-Scale Expression

• Transient transfection in HEK293 or CHO (96-well or 24-well format)

• Expression titer: Goal >1 g/L

• Purification: Protein A capture (automated, high-throughput)

G. Basic Biophysical Characterization

• SEC (size-exclusion chromatography): % monomer (goal >95%)

• DSF (differential scanning fluorimetry): Tm (goal >60°C for all domains)

• DLS (dynamic light scattering): Aggregation check (Rh < 10 nm)

H. High-Concentration Formulation Test

• Concentrate to 150 mg/mL (spin concentrator)

• Measure viscosity (viscometer)

• Monitor aggregation: Store 1 week at 40°C (accelerated stability)

Decision criteria:

• Pass: >95% monomer, Tm >60°C, viscosity <20 cP, <5% aggregation after 1 week at 40°C

• Output: 3-5 "developable" candidates advance to lead optimization

Stage 3: Lead Optimization (Affinity + Developability Co-Optimization)

Goal: Improve affinity while maintaining or improving developability

Affinity Maturation

Standard approaches:

• CDR diversification (site-directed mutagenesis, error-prone PCR)

• Library screening for improved Kd (goal <1 nM)

• Maintain or improve functional activity

Simultaneous Developability Optimization

Strategy 1: Remove aggregation hotspots

• Replace hydrophobic residues in CDRs with polar residues

• Target: Tyr → Ser, Phe → Thr, Trp → His (conservative hydrophobic → polar)

Strategy 2: Reduce viscosity

• Mutate surface charged residues to neutral

• Charge balancing: If positive patch exists, reduce positive charges (Lys → Gln, Arg → Gln)

Strategy 3: Improve thermal stability

• Introduce stabilizing mutations in framework regions

• Target: Fill cavities, improve hydrophobic packing, strengthen domain interfaces

Strategy 4: Remove chemical liabilities

• Mutate Asn-Gly → Asn-Ala (prevent deamidation)

• Avoid Met in CDRs (oxidation-prone), substitute with Leu or Ile

The Balancing Act: Affinity vs Developability

Challenge: Removing hydrophobic CDR residues may reduce affinity

Example:

• CDR-H3 has Tyr100 contacting antigen (π-π stacking with target)

• Tyr100 also drives aggregation (exposed hydrophobic patch)

• Mutating Y100S improves aggregation but loses affinity (2-5×)

Solution: Use AI to predict minimal-impact mutations

• Orbion suggests mutations with predicted ΔΔG binding <1 kcal/mol (affinity loss <3×)

• Test multiple mutations in parallel

• Select best trade-off (e.g., 2× affinity loss for 10× improved solubility = acceptable)

AI-Driven Optimization with Orbion

The Orbion Workflow

Step 1: Upload Antibody Sequences

Input:

• VH sequence (heavy chain variable region)

• VL sequence (light chain variable region)

• Optional: Full IgG sequence (includes constant regions)

Orbion generates:

• AlphaFold structure prediction (if no experimental structure)

• Domain annotations (FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4)

Step 2: Run Comprehensive Developability Analysis

Orbion analyzes (5 minutes):

1. Aggregation propensity: Surface hydrophobic patches (SASA-based scoring)

2. Viscosity prediction: Charge distribution analysis

3. Thermal stability: ΔΔG predictions for all domains (VH, VL, CH2, CH3)

4. PTM liabilities: Deamidation, oxidation, glycosylation sites

Output: Developability Scorecard

• Overall score: Pass / Marginal / Fail

• Individual scores for each CQA

• Flagged issues with severity (high/medium/low)

Step 3: Review Predicted Issues

Example output:

• ⚠️ High aggregation risk: CDR-H3 hydrophobic patch (Y98, Y99, F103)

• ⚠️ High viscosity: Charge patches on VH (K45, K67, K82) and VL (E42, E55)

• ✓ Thermal stability: All domains Tm >60°C

• ⚠️ Deamidation liability: Asn55-Gly56 in CDR-H2 (1%/month degradation)

• ✓ Glycosylation: Asn297 correctly predicted, no unintended sites

• ⚠️ Immunogenicity: 3 mouse residues in frameworks (positions 30, 48, 72)

Step 4: Get AI-Suggested Mutations

For each issue, Orbion suggests specific mutations:

Issue 1: Aggregation (CDR-H3 hydrophobic patch)

• Mutation: Y99S (Tyr → Ser)

• Prediction: 60% reduction in aggregation propensity

• Impact on affinity: ΔΔG = +0.6 kcal/mol (~2× affinity loss, acceptable)

• Confidence: High (trained on 1,000+ therapeutic antibody structures)

Issue 2: Viscosity (VH surface charge)

• Mutation: K45Q (Lys → Gln)

• Prediction: 30% reduction in charge patch size

• Impact on stability: ΔΔG = +0.1 kcal/mol (neutral)

• Confidence: Medium

Issue 3: Deamidation (CDR-H2 liability)

• Mutation: G56A (Gly → Ala)

• Prediction: 10× reduction in deamidation rate (Ala side chain restricts backbone)

• Impact on affinity: Minimal (conservative mutation)

• Confidence: High

Issue 4: Humanization (framework residues)

• Mutations: A30S, R48K, I72V (revert to human germline)

• Prediction: 40% reduction in T-cell epitope score

• Impact on stability: Minimal

• Confidence: High

Step 5: Design Optimized Variants

Create multiple variants to test in parallel:

• Variant 1: Y99S only (test aggregation fix)

• Variant 2: Y99S + K45Q (aggregation + viscosity)

• Variant 3: Y99S + G56A (aggregation + chemical stability)

• Variant 4: Y99S + K45Q + G56A + humanization (all fixes)

Orbion predicts performance for each variant:

• Expected aggregation, viscosity, Tm, affinity

Decision: Express top 3 variants for experimental validation

Step 6: Experimental Validation (4-6 weeks)

Express variants:

• Transient transfection in HEK293

• Purify by Protein A

• Yield: Measure expression titer

Biophysical characterization:

• SEC-MALS: % monomer (aggregation)

• Viscosity: Measure at 150 mg/mL

• DSF: Tm for all domains

• Binding assay (ELISA or SPR): Measure Kd (affinity)

Results example:

• Variant 1: 98% monomer, affinity 1.5× loss (acceptable)

• Variant 2: 97% monomer, viscosity 15 cP (excellent), affinity 2× loss

• Variant 4: 99% monomer, viscosity 12 cP, <2% deamidation at 4 weeks/40°C, affinity 2.5× loss

Decision: Variant 4 is lead candidate (best overall developability, acceptable affinity)

Glycosylation: The Critical Modification

Asn297 N-Glycosylation in the Fc

Every IgG has one N-glycosylation site per heavy chain: Asn297 in the CH2 domain.

Why it matters:

• Effector function: ADCC (antibody-dependent cellular cytotoxicity) and CDC (complement-dependent cytotoxicity) require glycosylation at Asn297

• Stability: Glycan stabilizes CH2 domain (Tm increases by ~10°C)

• Aggregation: Incorrect glycan structures promote aggregation

Glycan Structures and Their Impact

Core structure:

• GlcNAc2-Man3 (core pentasaccharide, conserved in all IgG)

Variations:

Core fucose (α1-6 linked to core GlcNAc):

• Present in ~95% of human IgG

• Impact: Reduces ADCC potency 10-50× (fucose blocks FcγRIIIa binding)

• Afucosylated antibodies: Enhanced ADCC (useful for oncology)

Galactose (β1-4 linked to core Man):

• G0 (no Gal): 20-30%

• G1 (1 Gal): 40-50%

• G2 (2 Gal): 10-20%

• Impact: Galactosylation enhances CDC

Sialic acid (α2-6 or α2-3 linked to Gal):

• <10% of serum IgG

• Impact: Anti-inflammatory (sialylated IgG has different FcR binding)

Glycoengineering for Enhanced Efficacy

Strategy 1: Afucosylation (enhanced ADCC)

• Use GlycoDelete CHO cells (FUT8 knockout, no fucosyltransferase)

• Result: 10-50× enhanced ADCC

• Example: Mogamulizumab (approved for T-cell lymphoma, afucosylated)

Strategy 2: Homogeneous glycosylation

• Engineer glycosylation pathways in CHO (express human glycosyltransferases)

• Result: Reduced heterogeneity, better product quality

Predicting Glycosylation with Orbion's AstraPTM2

What it does:

• Predicts N-glycosylation sites from sequence (Asn-X-Ser/Thr consensus)

• Predicts which sites are actually glycosylated (not all consensus sequences are modified)

• Flags unintended glycosylation sites in CDRs or frameworks

Why this matters:

• Unintended glycosylation in CDRs adds heterogeneity (complicates analytics)

• Low glycosylation efficiency at Asn297 may require expression system change (E. coli → mammalian)

• Additional sites can be engineered for therapeutic purposes (mask aggregation hotspots)

Real Rescue Case Studies

Case Study 1: Anti-TNF Antibody Viscosity Rescue

Background:

• Anti-TNF-α antibody for rheumatoid arthritis

• High affinity (Kd = 0.3 nM), excellent neutralization

• Problem: Viscosity 125 cP at 150 mg/mL (target <20 cP, failed Phase I)

Investigation (Orbion analysis):

• Charge patch analysis: Large positive patch on VH (7 Lys/Arg), large negative patch on VL (5 Glu/Asp)

• Strong electrostatic interactions drive self-association

Solution:

• Orbion suggests 8 mutations to reduce charge patches

• Design 4 variants: K50Q, K50Q+E52Q, K50Q+E52Q+K89Q, K50Q+E52Q+K89Q+R92Q

Results:

• Variant 3 (triple mutant): Viscosity 18 cP at 150 mg/mL ✓

• Affinity: Kd = 0.4 nM (1.3× loss, acceptable)

Outcome:

• Re-entered Phase I with optimized antibody

• Phase II completed successfully

• Time saved: 6 months vs traditional trial-and-error

• Cost saved: $15-25M

Case Study 2: Anti-HER2 Deamidation Liability Fix

Background:

• Anti-HER2 antibody, high efficacy in vivo

• Problem: 12% deamidation after 6 months at 4°C (shelf life issue)

• Deamidation site: Asn55-Gly56 in CDR-H2

• Deamidated antibody: 5× lower affinity

Solution:

• Mutation: G56A (Gly → Ala)

• Prediction: 10× reduction in deamidation rate

Results:

• Deamidation at 6 months: <2% (acceptable)

• Affinity: Unchanged (Gly → Ala is conservative)

• Charge heterogeneity: Minimal

Outcome:

• Achieved 24-month shelf life specification

• IND approved

• Impact: Avoided $50M+ program restart

Case Study 3: Anti-EGFR Aggregation Rescue

Background:

• High affinity (Kd = 0.5 nM), potent cell killing

• Problem: 15% aggregation at 100 mg/mL within 1 week

Investigation:

• AGGRESCAN3D: Hydrophobic patch in CDR-H3 (residues 98-103: YYYGDY)

• 3 Tyr residues create 300 Ų hydrophobic surface

Solution:

• Mutation: Y100S (Tyr → Ser in CDR-H3)

• Prediction: 70% reduction in aggregation, ΔΔG binding = +0.8 kcal/mol (2× loss acceptable)

Results:

• Affinity: Kd = 1.2 nM (2.4× loss, still excellent)

• Solubility: Stable at 150 mg/mL for 6 months

• Aggregation: <1% HMWS at shelf life

Outcome:

• IND approved, entered Phase I

• Lesson: One mutation rescued a $40M failed program

Practical Antibody Developability Checklist

At Discovery Stage

• [ ] Use human or humanized frameworks (reduce immunogenicity)

• [ ] Avoid long CDR-H3 (>18 amino acids increases aggregation risk)

• [ ] Run computational developability screen (Orbion) before committing resources

• [ ] Deprioritize candidates with predicted high-risk liabilities

At Lead Optimization Stage

• [ ] Measure affinity (SPR or ELISA): Target Kd <1 nM

• [ ] SEC-MALS: Target >95% monomer at 10 mg/mL

• [ ] DSF: Target Tm >60°C for all domains (VH, VL, CH2, CH3)

• [ ] Small-scale concentration test: Can you reach 100 mg/mL?

• [ ] Deamidation/oxidation scan: Identify liability sites (peptide mapping)

• [ ] Humanness check: <5 non-human residues in frameworks

Before IND

• [ ] Full formulation screening (pH, buffer, excipients)

• [ ] Stability: 24 months at 2-8°C, <2% HMWS

• [ ] Viscosity at 150 mg/mL: <20 cP (injectable)

• [ ] Manufacturing: >3 g/L titer in CHO fed-batch

• [ ] Immunogenicity: T-cell epitope removal, NHP ADA testing

• [ ] CMC (Chemistry, Manufacturing, Controls) package complete

The Economics of Early Screening

Traditional Approach (No Early Screening)

Timeline:

• Discovery: 12 months

• Lead optimization: 12 months

• IND-enabling: 12 months

• Developability failure discovered in Phase I: Total 36 months, $40-80M wasted

Success rate: 20-30% of candidates pass developability

Modern Approach (AI-Driven Early Screening)

Timeline:

• Discovery: 12 months

• Computational screening: 1-2 weeks (Orbion analysis)

• Rapid experimental validation: 4 weeks

• Lead optimization (focused on developable candidates): 6-9 months

• IND-enabling: 12 months

• Total to IND: 30 months

Success rate: 60-70% of candidates pass developability (pre-filtered)

ROI:

• Time saved: 6 months faster to IND

• Cost saved: $20-50M per program (avoid late-stage failures)

• Success rate improvement: 3× higher probability of approval

The Bottom Line

Antibody developability is engineerable. With modern AI tools, you can predict liabilities in minutes and design fixes in weeks—not discover problems in Phase II after spending $100M.

The new workflow:

1. Generate antibody candidates (phage display, B-cell cloning)

2. Computationally screen for developability (Orbion, 5 minutes per candidate)

3. Filter out high-risk candidates

4. Experimentally validate top 10-20

5. Advance 3-5 developable leads to optimization

6. Result: 3× higher success rate, 6-12 months faster

The mutations that matter:

• 1-3 well-placed mutations can rescue a failed candidate

• Typical trade-off: 2× affinity loss for 10× improved developability (acceptable)

• AI tools identify these mutations in minutes

The competitive advantage:

• Companies using early developability screening: 60-70% Phase I success rate

• Companies without screening: 20-30% success rate

• The difference: $50-150M saved per program, 1-2 year advantage over competitors

Ready to Engineer Your Antibody for Success?

If you have an antibody candidate and want to optimize developability before investing in clinical trials, Orbion can help.

Orbion provides:

• Aggregation hotspot prediction with specific mutation recommendations

• Viscosity prediction and charge-balancing strategies

• Thermal stability optimization (ΔΔG for all domains)

• PTM liability detection (deamidation, oxidation, glycosylation)

• Immunogenicity risk assessment with humanization suggestions

• Complete developability scorecard in minutes